Scroll Back to Top
 Shot of a senior woman looking thoughtful in a retirement home

Ovarian Cancer 

Labcorp Oncology offers a comprehensive test menu to support you in the diagnosis and treatment of patients with ovarian cancer throughout their continuum of care.

supporting image
DNA icon

Genetic Risk Assessment

Genetic Risk

BRCAssure® BRCA1/2 Analysis

  • Mutations in BRCA1 and BRCA2 account for the vast majority of families with hereditary breast and ovarian cancer syndrome (HBOC).
  • The estimated lifetime risk for breast and ovarian cancer is significantly increased in women with BRCA1/2 mutations.1

Learn more about BRCAssure® BRCA1/2 Analysis

Genetic Risk

VistaSeq® Hereditary Cancer Panels

  • Provide an assessment of genetic mutations known to be associated with hereditary cancer syndromes.  Available panels include:
    • Hereditary Cancer Panel
    • Hereditary Cancer Panel minus BRCA1/2 genes
    • GYN Cancer Panel
    • Breast Cancer Panel
    • Breast and GYN Cancer Panel
  • Genetic tests, like VistaSeq and BRCAssure, inform a patient's risk of cancer and may guide therapy for patients with cancer.
  • Mutation-specific sequencing for patients with a family history of known germline mutations is also available.

Learn more about VistaSeq® Hereditary Cancer Panels

Diagnostic Icon



Complex Tumor Analysis by IHC

Our extensive antibody library and team of pathologists can provide a differential diagnostic analysis in even the most complex cases.

CDX2/CK7 by IHC – useful to distinguish stomach and colon carcinoma from ovarian carcinoma.

Learn more about Complex Tumor Analysis by IHC


p53 by IHC

Abnormal expression of p53 can help distinguish between low grade and high grade serous ovarian carcinomas.

Learn more about p53 by IHC

Clipboard Icon



Ovarian Malignancy Risk (ROMA®)

The ROMA® (Risk of Ovarian Malignancy Algorithm) calculation combines the results of the Roche Elecsys HE4 assay, Elecsys CA 125 II assay and menopausal status into a numerical score.

The ROMA value is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian mass is at high or low likelihood of finding malignancy at the time of surgery.

Learn more about Ovarian Malignancy Risk (ROMA®)


BRAF Gene Mutation Analysis

This test will detect all V600 mutations of the BRAF oncogene frequently found in human cancers, including ovarian cancer, allowing the determination of drug response, aiding the diagnosis and providing prognosis information.

BRAF mutation is associated with early-stage disease and Improved outcomes in patients with low-grade serous ovarian cancer.2

Learn more about BRAF Gene Mutation Analysis

Predictive icon

Biomarkers for Therapeutic Selection

Biomarkers and tests for clinical management and treatment decision-making

FOLR1 by IHC   
Folate Receptor 1 protein (FOLR1 or FRɑ) expressionMirvetuximab soravtansine-gynx for patients with platinum-resistant ovarian cancer 3
ER by IHC 
PR by IHC 
ER/PR protein expression Hormonal therapies 
BRAF Gene Mutation AnalysisMutations in the BRAF gene (e.g., V600E)BRAF inhibitor
Microsatellite Instability (MSI) or Mismatch Repair (MMR) Proteins by IHC Microsatellite instability (MSI)/ mismatch repair (MMR) deficiency Pembrolizumab4, dostarlimab-gxly5
OmniSeq® INSIGHT, Solid Tumor NGS Panel (DNA and RNA) Includes DNA and RNA sequencing (523 genes), MSI, TMB*, fusion analysis including NTRK and RET, PD-L1 IHC and immune gene profiling Targeted therapies and immunotherapies 
BRCAssure® BRCA1/2Analysis BRCA1 and BRCA2 gene mutations PARP inhibitor 
VistaSeq® Hereditary Cancer Panels BRCA1, BRCA2, and other hereditary cancer gene mutations PARP inhibitor 

*TMB - tumor mutational burden

Calendar Icon


Ovarian cancer specific blood-based tumor markers


CA 125

Primarily for epithelial ovarian cancer

Learn more about CA 125



For mucinous ovarian cancer

Learn more about CEA


Inhibin A and B

For granulosa cell ovarian cancers

Learn more about Inhibin A and B


Human epididymis protein 4 (HE4)


α-Fetoprotein (AFP)

For germ cell ovarian cancers

Learn more about α-Fetoprotein (AFP)


Human chorionic gonadotropin (hCG, β-subunit)



  1. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [updated 2022 May 26]. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2023. PMID: 20301425.
  2. Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013 Feb 1;119(3):548-554. doi: 10.1002/cncr.27782. Epub 2012 Aug 28. PMID: 22930283; PMCID: PMC3961140.
  3. ELAHERE® (mirvetuximab soravtansine-gynx) [package insert]. ImmunoGen, Inc., MA; 2022.
  4. KEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck &Co., Inc.; 2021.
  5. JEMPERLI (dostarlimab-gxly) [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; 2023.